Document 0282
 DOCN  M9550282
 TI    Persistent enhancement after treatment for cerebral toxoplasmosis in
       patients with AIDS: predictive value for subsequent recurrence.
 DT    9505
 AU    Laissy JP; Soyer P; Parlier C; Lariven S; Benmelha Z; Servois V;
       Casalino E; Bouvet E; Sibert A; Vachon F; et al; Department of
       Radiology, Hopital Bichat, Paris, France.
 SO    AJNR Am J Neuroradiol. 1994 Oct;15(9):1773-8. Unique Identifier :
       AIDSLINE MED/95149874
 AB    PURPOSE: To determine the predictive imaging (CT and/or MR) features of
       brain toxoplasmosis recurrences in acquired immunodeficiency syndrome.
       METHODS: The imaging studies of patients with brain toxoplasmosis were
       retrospectively reviewed. Forty-three patients with significant decrease
       or disappearance of brain lesions under specific treatment on follow-up
       imaging examinations were included. MR examinations were performed using
       T2- and T1-weighted sequences, before and after intravenous
       administration of gadolinium-DOTA. RESULTS: A recurrence occurred in 11
       (26%) of 43 cases. Ten (91%) of these 11 patients with recurrence showed
       focal persistent enhancement after the initial treatment of
       toxoplasmosis abscess. One of the 11 patients with recurrence showed no
       persistent enhancement; 3 patients showed persistent enhancement but had
       no recurrence. CONCLUSIONS: Recurrences of brain toxoplasmosis in our
       series correlated with persistent contrast enhancement. We hypothesize
       that demonstration of persistent areas of contrast enhancement after
       treatment for initial toxoplasmosis may be a valuable sign for
       identifying patients at risk for recurrence.
 DE    Adult  Aged  Atrophy  AIDS-Related Opportunistic
       Infections/DIAGNOSIS/*DRUG THERAPY  Brain/PATHOLOGY  Brain
       Abscess/DIAGNOSIS/DRUG THERAPY  Drug Therapy, Combination
       Encephalomalacia/DIAGNOSIS  Female  Follow-Up Studies  Human  *Magnetic
       Resonance Imaging  Male  Middle Age  Pyrimethamine/*THERAPEUTIC USE
       Recurrence  Sulfadiazine/*THERAPEUTIC USE  Toxoplasmosis,
       Cerebral/DIAGNOSIS/*DRUG THERAPY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).